Floatz logo

ETHYLICUM

Alcohol Consumption

The University of Texas Health Science Center at San AntonioSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Alcohol Consumption cohort.

Asset / SponsorPhaseRating
Naltrexone
Boston Medical Center
Phase 4BB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
Boston Medical Center
Phase 2B
TEONANACATL
Centre for Addiction and Mental Health
Phase 2CCC
Zonisamide
Yale University
Phase 2CCC
Pemvidutide
Altimmune, Inc.
Phase 2CCC

View all 19 →

Same molecule, other indications

ETHYLICUM is also rated in:

malignant pancreatic neoplasmDormant
BB
Indicative ·
66 / 100
View asset →
Abdominal CancerDormant
BB
Indicative ·
66 / 100
View asset →
cancer-related conditionDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →